dr. garassino on qol findings from the flaura study in nsclc
Published 6 years ago • 65 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:05
dr. garassino discusses promising findings with osimertinib for patients with nsclc and brain mets
-
1:36
dr. garassino discusses recent pivotal immunotherapy findings in nsclc
-
1:30
dr. garassino on erlotinib/ramucirumab versus osimertinib in egfr nsclc
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
1:55
dr. bauml discusses the flaura study in nsclc
-
1:34
dr. garassino on the pacific trial for nsclc
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
31:06
dr. garassino: navigating a path to leadership in thoracic oncology research and education in italy
-
1:50
dr. levy discusses the flaura study in lung cancer
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc
-
0:38
a day in the life of: dr tozaki, breast cancer expert | ge healthcare
-
1:12:38
the ins and outs of a seemingly easy cancer—thyroid cancer
-
0:39
rationale for targeting fpr2 in female patients with pancreatic cancer
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
7:45
upfront use of osimertinib in egfr nsclc
-
0:52
dr. saettele on the benefits of using bronchoscopies in nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:54
dr. gainor on the pacific-2 trial in stage iii nsclc